TGNA:FRA
Transgene SA
€0.67
arrow_downward
-0.15%(-0.00100) 1D
Oct 13, 8:03:08 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
€0.67
High
€0.67
Low
€0.67
Mkt. cap
192.76M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
152
Open
€0.67
High
€0.67
Low
€0.67
Mkt. cap
192.76M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
152
News stories
From web sources and news partners
The Lufkin Daily News
·
53 minutes ago
S&P 500, Dow futures muted after big bank earnings, chip slide weighs
24/7 Wall St.
·
1 hour ago
Buffett Says a Know-Nothing Investor Can Beat the Pros. $250 a Month in the S&P 500 Could Turn Into $508,000
Yahoo Finance
·
58 minutes ago
If I Could Invest $1,000 in Just 1 Dividend Stock for the Next 5 Years, I'd Pick This Clear Standout Over the Vanguard S&P 500 ETF (VOO)
CNBC
·
1 hour ago
S&P 500 futures are mixed ahead of bank earnings
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA